AnaptysBio (NASDAQ:ANAB) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of their ...

Ratings for AnaptysBio ANAB were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below ...

AnaptysBio stock zoomed higher Wednesday after announcing a $100 million offering that includes participation from pharma ...

On Thursday, H.C. Wainwright analyst Emily Bodnar increased the price target on AnaptysBio (NASDAQ:ANAB) shares to $22.00, up from the previous $19.00, while maintaining a Neutral rating on the stock.

JPMorgan raised the firm’s price target on AnaptysBio (ANAB) to $42 from $36 and keeps an Overweight rating on the shares. The firm updated models in the Smid-cap biotechnology group.

Has AnaptysBio, Inc. (ANAB) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Guggenheim raised the firm’s price target on AnaptysBio (ANAB) to $52 from $36 and keeps a Buy rating on the shares following the company’s Q4 update. The firm is “encouraged” by the ...

AnaptysBio, Inc. (ANAB) shares rallied 30.5% in the last trading session to close at $16.15. This move can be attributable to notable volume with a higher number of shares being traded than in a ...